Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : GILD crawled time : 22:00 save search
Gilead Sciences Announces Completion of Acquisition of CymaBay
Published: 2024-03-22 (Crawled : 22:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.03%
H: 0.16%
C: -0.68%
acquisition sciences
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
Published: 2024-02-28 (Crawled : 22:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.03%
H: 0.26%
C: -0.85%
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
year update financial results
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
Published: 2023-08-18 (Crawled : 22:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.07%
H: 0.21%
C: -0.88%
initiative sciences hiv impact medical
GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION’S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030
Published: 2023-07-28 (Crawled : 22:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.12%
H: 1.18%
C: 0.58%
hepatitis health world global grant program
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
Published: 2023-06-08 (Crawled : 22:00) - biospace.com/
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.41%
H: 0.68%
C: 0.64%
PGEN | $1.33 0.76% 0.75% 1M
|
Health Technology
|
| O: 0.0%
H: 0.76%
C: -4.55%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.63%
H: 1.87%
C: -1.25%
ITOS | $10.58 2.42% 2.36% 940K
|
Health Technology
|
| O: -0.52%
H: 3.23%
C: -2.2%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.42%
H: 3.56%
C: 3.48%
cancer
Galapagos announces full year 2022 results and outlook for 2023
Published: 2023-02-23 (Crawled : 22:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.33%
H: 0.04%
C: -1.96%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -7.42%
H: 5.64%
C: 4.06%
year
THE ELIZABETH TAYLOR AIDS FOUNDATION AND THE HIV IS NOT A CRIME CAMPAIGN WIN BIG AT THE ANTHEM AWARDS
Published: 2023-02-15 (Crawled : 22:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.87%
H: 0.53%
C: -1.09%
awards hiv
Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
Published: 2022-12-27 (Crawled : 22:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.46%
H: 0.5%
C: -0.97%
gs-1811 immunotherapy potential
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
Published: 2022-12-07 (Crawled : 22:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.08%
H: 0.59%
C: -0.27%
yescarta japan t-cell agreement therapy
Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Congress
Published: 2022-10-20 (Crawled : 22:00) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 3.17%
H: 7.69%
C: -2.56%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.03%
H: 2.66%
C: 2.43%
immunotherapy meeting therapeutics
Celularity Reports Second Quarter 2022 Financial Results and Corporate Update
Published: 2022-08-09 (Crawled : 22:00) - biospace.com/
CELU | News F | $3.09 -3.74% -3.88% 24K
|
|
| O: -0.97%
H: 4.23%
C: 1.95%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.03%
H: 0.76%
C: 0.68%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.03%
H: 1.02%
C: 0.47%
update results
Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
Published: 2022-06-03 (Crawled : 22:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -2.01%
H: 0.0%
C: 0.0%
yescarta t-cell therapy
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
Published: 2022-02-16 (Crawled : 22:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.21%
H: 1.72%
C: 1.14%
hiv
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-02-01 (Crawled : 22:00) - biospace.com/
RCUS 4 | $14.59 -1.69% 0.0% 600K
|
Health Technology
|
| O: 0.97%
H: 1.48%
C: 1.19%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.16%
H: 0.01%
C: -0.47%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -1.14%
H: 2.85%
C: 2.65%
financial results ces results
HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention
Published: 2021-12-21 (Crawled : 22:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.0%
H: 0.17%
C: -0.87%
fda health thc approval injection hiv
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
zuma-12 yescarta treatment risk t-cell
GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH
Published: 2021-11-18 (Crawled : 22:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.36%
H: 0.3%
C: -0.65%
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: -1.54%
H: 2.15%
C: 0.06%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.59%
H: 1.04%
C: 0.74%
GNFT | $3.59 4.03% 2.1K
|
Health Technology
|
| O: 5.07%
H: 1.14%
C: -0.27%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.61%
H: 0.45%
C: 0.39%
nis4 unique risk technology nash
Gilead Sciences Announces Third Quarter 2021 Financial Results
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.1%
H: 1.44%
C: 0.96%
financial results results
Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.1%
H: 1.44%
C: 0.96%
collaboration cancer breast cancer trial keytruda
Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021
Published: 2021-10-14 (Crawled : 22:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.86%
H: 0.76%
C: -0.09%
financial results results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.